Skip to content
Subscriber Only

Pfizer Raises Profit Forecast Amid Pressure on Drug Prices

  • Company raises earnings guidance, lowers revenue midpoint
  • Pfizer delayed price hikes after pressure from President Trump
Updated on

Pfizer Inc. increased its full-year earnings outlook, a sign of relative confidence in profitability amid weaker revenue and pressure on drug prices from the Trump administration.

The New-York-based drugmaker now sees earnings of $2.95 to $3.05 a share, excluding some items, after its second-quarter profit beat Wall Street estimates. Analysts anticipated $2.95 for the full year, on average.